The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A SIMPLIFIED METHOD OF EVALUATING DOSE-EFFECT EXPERIMENTS
LITCHFIELD, J. T., & WILCOXON, F. (1949) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)03549-9 · Cited by 7,812
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“Previous studies (e.g., Santarelli et al., 2003) have also suggested that 5-HT1A receptor activation mediates the effects of selective SSRI on the hippocampus neurogenesis, which is considered to underlie the anxiolyticand antidepressant-like effects of chronic administration with SSRI.”
Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis
Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., & Davis, J. M. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61764-x · Cited by 1,930
Muscarinic Cholinergic Binding in Rat Brain
Yamamura, H. I., & Snyder, S. H. (1974) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.71.5.1725 · Cited by 1,203
Kroeze, W. K., Hufeisen, S. J., Popadak, B. A., Renock, S. M., Steinberg, S., Ernsberger, P., Jayathilake, K., Meltzer, H. Y., & Roth, B. L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300027 · Cited by 801
Serotonin receptors : their key role in drugs to treat schizophrenia
Meltzer, H. Y., Li, Z., Kaneda, Y., & Ichikawa, J. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2003.09.010 · Cited by 775
The olfactory bulbectomized rat as a model of depression: An update
Kelly, J. P., Wrynn, A. S., & Leonard, B. E. (1997) · Pharmacology & Therapeutics · doi:10.1016/s0163-7258(97)00004-1 · Cited by 662
Positive and Negative Symptoms in Schizophrenia: A Critical Reappraisal
Andreasen, N. C. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810190015002 · Cited by 410 · cited 1×
“…negative symptoms (e.g., flattened affect, apathy, and social withdrawal), dysphoric mood symptoms (e.g., anxiety and depression), and cognitive dysfunction (e.g., deficit in working memory, executive function, attentional processing, and memory) (Andreasen et al., 1990; Meltzer, 1999).”
BackgroundFunctional, molecular and pharmacological advances in 5-HT receptor research
HEDLUND, P., & SUTCLIFFE, J. (2004) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.07.002 · Cited by 350
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Millan, M. J. (2000) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38982-7 · Cited by 287
Cited by
Miyamoto, S., Miyake, N., Jarskog, L. F., Fleischhacker, W. W., & Lieberman, J. A. (2012) · Molecular Psychiatry · doi:10.1038/mp.2012.47 · Cited by 573
Kaar, S. J., Natesan, S., McCutcheon, R., & Howes, O. D. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107704 · Cited by 383
The role of serotonin receptors in the action of atypical antipsychotic drugs
Meltzer, H., & Massey, B. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.007 · Cited by 381
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Hsu, J., Sarma, K., & Sachs, G. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070984 · Cited by 341
Suppes, T., Silva, R., Cucchiaro, J., Mao, Y., Targum, S., Streicher, C., Pikalov, A., & Loebel, A. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.15060770 · Cited by 322
Loebel, A., Cucchiaro, J., Silva, R., Kroger, H., Sarma, K., Xu, J., & Calabrese, J. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2013.13070985 · Cited by 293
Dopamine Targeting Drugs for the Treatment of Schizophrenia: Past, Present and Future
Li, P., L. Snyder, G., & E. Vanover, K. (2016) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026616666160608084834 · Cited by 266
Barnes, N. M., Ahern, G. P., Becamel, C., Bockaert, J., Camilleri, M., Chaumont-Dubel, S., Claeysen, S., Cunningham, K. A., Fone, K. C., Gershon, M., et al. (2021) · Pharmacological Reviews · doi:10.1124/pr.118.015552 · Cited by 263
Treating comorbid anxiety and depression: psychosocial and pharmacological approaches
Coplan, J. D. (2015) · World Journal of Psychiatry · doi:10.5498/wjp.v5.i4.366 · Cited by 207
DelBello, M. P., Goldman, R., Phillips, D., Deng, L., Cucchiaro, J., & Loebel, A. (2017) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1016/j.jaac.2017.10.006 · Cited by 135
Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A., & Ove Ögren, S. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.016 · Cited by 132
Vortioxetine: a novel antidepressant for the treatment of major depressive disorder
Gonda, X., Sharma, S. R., & Tarazi, F. I. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1546691 · Cited by 123
Cerovecki, A., Musil, R., Klimke, A., Seemüller, F., Haen, E., Schennach, R., Kühn, K.-U., Volz, H.-P., & Riedel, M. (2013) · CNS Drugs · doi:10.1007/s40263-013-0079-5 · Cited by 112
The Burden of Antipsychotic-Induced Weight Gain and Metabolic Syndrome in Children
Libowitz, M. R., & Nurmi, E. L. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.623681 · Cited by 99
Reynolds, G. P., & McGowan, O. O. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117722987 · Cited by 67
Citrome, L., Stensbøl, T. B., & Maeda, K. (2015) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2015.1086269 · Cited by 63
Kato, T., Ishigooka, J., Miyajima, M., Watabe, K., Fujimori, T., Masuda, T., Higuchi, T., & Vieta, E. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13137 · Cited by 49
Correll, C. U., Cucchiaro, J., Silva, R., Hsu, J., Pikalov, A., & Loebel, A. (2016) · CNS Spectrums · doi:10.1017/s1092852915000917 · Cited by 48
Calabrese, F., Luoni, A., Guidotti, G., Racagni, G., Fumagalli, F., & Riva, M. A. (2013) · Psychopharmacology · doi:10.1007/s00213-012-2900-0 · Cited by 43
Yuen, E. Y., Li, X., Wei, J., Horiguchi, M., Meltzer, H. Y., & Yan, Z. (2012) · Molecular Pharmacology · doi:10.1124/mol.111.076141 · Cited by 38
Tsai, J., Thase, M. E., Mao, Y., Ng-Mak, D., Pikalov, A., & Loebel, A. (2017) · CNS Spectrums · doi:10.1017/s1092852917000074 · Cited by 22
‘Hidden’ HCN channels permit pathway-specific synaptic amplification in L2/3 pyramidal neurons
Oláh, V. J., Wu, J., Kaczmarek, L. K., & Rowan, M. J. (2024) · doi:10.7554/elife.96002.1 · Cited by 2
Metadata
- Authors
- Ishibashi, T., Horisawa, T., Tokuda, K., Ishiyama, T., Ogasa, M., Tagashira, R., Matsumoto, K., Nishikawa, H., Ueda, Y., Toma, S., Oki, H., Tanno, N., Saji, I., Ito, A., Ohno, Y., & Nakamura, M.
- Venue
- The Journal of Pharmacology and Experimental Therapeutics
- Publisher
- Elsevier BV
- Published
- 2010-07
- Volume
- 334
- Issue
- 1
- Pages
- 171-181
- ISSN
- 0022-3565 (ISSN-L)
- OpenAlex
- W2137044087
- Cited by
- 438
- References
- 42
- FWCI
- 17.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.